News

August 8, 2023
Oncolytics Biotech® Successfully Raises US$15 Million to Advance Breast and Pancreatic Cancer Clinical Programs
August 4, 2023
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity’s 43rd Annual Growth Conference
August 4, 2023
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
July 31, 2023
Oncolytics Biotech® Announces US$15 Million Bought Deal Offering of Units
June 22, 2023
Oncolytics Biotech’s® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
June 5, 2023
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate
May 26, 2023
Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting
May 25, 2023
Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract
May 10, 2023
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
May 5, 2023
Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.ca

Email Alerts Sign-Up